Research Use Only. WADA-Prohibited. Oncological Risk. No clinically validated human LR3 dose exists. Significant IGF-1 pathway safety considerations. Do NOT automatically stack with GH secretagogues — Joseph explicit caution flag.
IGF-1 LR3 Protocol Reference
Practice context, oncological safety note, IGF-axis considerations, and cautious sourcing guidance.
Sourced Protocol Frameworks
Source: Physician Practice Literature (very limited)Protocol philosophy: No clinically validated human LR3 dose exists. Practice-described ranges are not validated clinical standards. The oncological risk from IGF-1 pathway activation must be prominently acknowledged in any research context.
PRACTICE NOTENo clinically validated human LR3 dose. Some physician-reviewed material describes ~50 mcg SC on weekdays — this is not an established clinical standard.
CRITICAL CAUTIONDo NOT automatically stack with GH secretagogues. Joseph explicitly flags overlapping IGF-axis signaling (GH secretagogues → endogenous IGF-1 + exogenous LR3) as a reason for careful consideration and monitoring.
ONCOLOGYIGF-1 pathway activation has established roles in cancer cell proliferation. This is not a minor caveat — it is a material safety consideration that should prominently inform any research context.
Reconstitution Reference
Calculation Example — 1 mg Vial
VIAL CONTENT
1 mg (1,000 mcg)
DILUENT
BAC water + 0.1% acetic acid (for solubility)
EXAMPLE VOLUME
2.0 mL
CONCENTRATION
500 mcg/mL
50 mcg DOSE
0.1 mL = 10 units U-100
STORAGE
Refrigerated 4°C
⚠ Arithmetic example only. Some LR3 preparations require acetic acid for complete solubility. Verify with specific product specifications. No universal standard.
Cycle & Safety Considerations
| Parameter | Framework | Source |
|---|---|---|
| Cycle | No validated cycle length | Physician practice (limited) |
| IGF-axis monitoring | Required — overlapping signaling with GH axis | Joseph caution flag |
| Oncological consideration | Prominent and material — not minor caveat | Established pharmacology |
| Reassessment | Frequent given safety profile | Protocol safety |
Pairing Cautions
| Compound | Relationship | Sequencing |
|---|---|---|
| BPC-157 | Recovery stack — less direct axis overlap | Cautious approach |
| GH secretagogues | Do NOT automatically stack — axis overlap | Joseph explicit caution flag |
| Oncological risk | IGF-1 axis cancer cell proliferation role | Not a minor consideration |
Evidence Status
| Category | Status |
|---|---|
| Overall | Research compound — no established clinical dosing |
| Human data | Physician practice (very limited) — no validated RCTs |
| Oncological risk | IGF-1 pathway has cancer cell proliferation role |
| WADA status | Prohibited — IGF-1 class compounds |
Source IGF-1 LR3 at Forge Scientific
Third-party tested, HPLC + Mass Spec verified, lot-specific COA. Ships same day — Fort Worth, TX.